CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer Center, and founder of the Institute for Myeloma & Bone Cancer Research, about toxicities associated with ruxolitinib (Jakafi) combination therapy, as well as strategies for reducing them. Additionally, the synergistic effects of adding ruxolitinib to selinexor were discussed.
